NEW YORK, March 24, 2017 /PRNewswire/ --
On Thursday, March 23, 2017, the NASDAQ Compositeended the trading session at 5,817.69, down 0.07%; the Dow Jones Industrial Average edged 0.02% lower, to finish at 20,656.58; and the S&P 500 closed at 2,345.96, marginally dropping 0.11%. US markets saw a mixed session as 4 sectors closed in green,
On Thursday, shares in Raleigh, North Carolina headquartered BioDelivery Sciences International Inc. ended the session 0.26% lower at $1.92 with a total volume of 344,458 shares traded. BioDelivery Sciences International's shares have advanced 1.32% in the past three months. The stock is trading 1.10% below its 50-day moving average and 12.90% below its 200-day moving average. Moreover, shares of the Company, which engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction, have a Relative Strength Index (RSI) of 47.27. Sign up and read the free research report on BDSI at:
On Thursday, shares in Cambridge, Massachusetts headquartered Sage Therapeutics Inc. recorded a trading volume of 374,883 shares. The stock ended the day 1.35% lower at $65.09. Sage Therapeutics' stock has gained 5.10% in the last one month and 36.97% in the previous three months. Furthermore, the stock has rallied 123.68% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 11.82% and 40.22%, respectively. Furthermore, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 52.04. The complimentary research report on SAGE can be downloaded at: http://stock-callers.com/registration/?symbol=SAGE
North Sydney, Australia headquartered Benitec Biopharma Ltd's stock finished Thursday's session 0.43% lower at $2.27 with a total volume of 27,331 shares traded. Over the last three months and the previous one year, Benitec Biopharma's shares have surged 59.42% and 29.72%, respectively. The Company's shares are trading above its 200-day moving average by 29.63%. Shares of Benitec Biopharma, which develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia, the UK, and the US, have an RSI of 45.10. Register for free on Stock-Callers.com and access the latest report on BNTC at:
Bothell, Washington headquartered OncoGenex Pharmaceuticals Inc.'s stock edged 0.23% lower, to close the day at $0.48. The stock recorded a trading volume of 80,068 shares. OncoGenex Pharma's shares have advanced 4.54% in the last three months. The Company's shares are trading 14.00% and 22.56% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops and commercializes therapies that address treatment resistance in cancer patients, have an RSI of 35.44. Get free access to your research report on OGXI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!